Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

2 Tower Place, Suite 2000, South San Francisco, United States

OriginalTradeonrumor Mar. 13 at 4:12 PM

$LAB spot on…though I do think their are fundamental potentials that can shoot this back up to well over 1.50 pretty quickly ..:but yes doing the scalp along the way makes total sense

0 · Reply

OriginalTradeonrumor Mar. 13 at 2:46 PM

$LAB been buying today in the .93-.945 area 😁

0 · Reply

Gunnar1 Mar. 12 at 6:05 PM

$LAB I like this stock because of the daily chart: price has reached absolute support, RSI and KDJ are oversold. This support needs to hold, then it's a triple bottom. Starting at level around 0.9-1.00$, the price has risen significantly again and again in the last 2.5 years. I'm loading up a starter and will get out immediately if the price falls below 90 cents. But if this support holds, there's easily 20%++ in it over the next few weeks. I will not marry this stock for sure... High risk, so take it with a grain of salt.

0 · Reply

lousyknees Mar. 12 at 2:56 PM

$LAB At this rate, we might be looking at a RS down the road.

1 · Reply

lousyknees Mar. 9 at 5:30 PM

$LAB Never thought I would see .97 cents a share with LAB. Just sell it for$5.00 and call it a day. Put us out of this LAB purgatory.

1 · Reply

Facade78 Mar. 4 at 5:56 PM

$LAB Float 2.8%, insider +280%, tuts own 77% and cash on hand.

1 · Reply

Wisenheimer Mar. 3 at 12:30 AM

$LAB warned about the reverse about 3 weeks ago

1 · Reply

Jkpga Mar. 2 at 7:09 PM

$LAB just split so the big boys would be more interested

0 · Reply

OfficialStocktwitsUser Feb. 25 at 6:44 PM

$LAB RSI: 35.21, MACD: -0.0795 Vol: 0.11, MA20: 1.23, MA50: 1.38 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GreenPond Feb. 25 at 1:40 PM

$LAB Info sharing ONLY. Good read about their M&A strategy and insights. https://www.investing.com/news/transcripts/standard-biotools-at-keybanc-forum-strategic-moves-in-plasma-proteomics-93CH-3938134

1 · Reply

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 7:00 AM EST - 4 weeks ago

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 30, 2026, 9:09 AM EST - 6 weeks ago

Standard BioTools Completes Sale of SomaLogic to Illumina

Jan 8, 2026, 7:00 AM EST - 2 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Nov 19, 2025, 11:30 AM EST - 4 months ago

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 4 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

Nov 4, 2025, 4:05 PM EST - 4 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 7:00 AM EDT - 5 months ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 6 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Jun 23, 2025, 7:13 AM EDT - 9 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 9 months ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

May 30, 2025, 7:00 AM EDT - 10 months ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 8:08 PM EDT - 11 months ago

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 4:01 PM EDT - 11 months ago

Standard BioTools Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 11 months ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 11 months ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Standard BioTools to Participate in Upcoming Investor Conferences

Feb 26, 2025, 9:44 PM EST - 1 year ago

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 1 year ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 7:10 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Aug 28, 2024, 8:58 AM EDT - 1 year ago

Standard BioTools And 2 Other Penny Stocks Executives Are Buying

Aug 27, 2024, 9:15 AM EDT - 1 year ago

Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying

Jul 31, 2024, 8:34 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

May 28, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO CTKB DHR MASS OMIC QGEN

May 20, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2024, 12:45 PM EDT - 2 years ago

Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 2 years ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 2 years ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 18, 2024, 8:12 AM EDT - 2 years ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Feb 28, 2024, 8:44 PM EST - 2 years ago

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 2 years ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 2 years ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

OriginalTradeonrumor Mar. 13 at 4:12 PM

$LAB spot on…though I do think their are fundamental potentials that can shoot this back up to well over 1.50 pretty quickly ..:but yes doing the scalp along the way makes total sense

0 · Reply

OriginalTradeonrumor Mar. 13 at 2:46 PM

$LAB been buying today in the .93-.945 area 😁

0 · Reply

Gunnar1 Mar. 12 at 6:05 PM

0 · Reply

lousyknees Mar. 12 at 2:56 PM

$LAB At this rate, we might be looking at a RS down the road.

1 · Reply

lousyknees Mar. 9 at 5:30 PM

$LAB Never thought I would see .97 cents a share with LAB. Just sell it for$5.00 and call it a day. Put us out of this LAB purgatory.

1 · Reply

Facade78 Mar. 4 at 5:56 PM

$LAB Float 2.8%, insider +280%, tuts own 77% and cash on hand.

1 · Reply

Wisenheimer Mar. 3 at 12:30 AM

$LAB warned about the reverse about 3 weeks ago

1 · Reply

Jkpga Mar. 2 at 7:09 PM

$LAB just split so the big boys would be more interested

0 · Reply

OfficialStocktwitsUser Feb. 25 at 6:44 PM

0 · Reply

GreenPond Feb. 25 at 1:40 PM

1 · Reply

GreenPond Feb. 25 at 1:14 PM

$LAB “On the cover: #Imaging mass cytometry image showing immune checkpoint inhibitor–induced lichen planus, with B-cell aggregates surrounded by T cells and macrophages. “ “ Image processing and analysis were conducted with Visiopharm® software. “ https://x.com/thejidjournal/status/2025237502127145038?s=46&t=NeTgmFeyCs0TcHAfvPzFYw

0 · Reply

Estimize Feb. 25 at 11:03 AM

$LAB reported 0.05 EPS and 23.80 revenue for Q4. http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_content=LAB&utm_med

0 · Reply

Xanderzzzzzzz Feb. 24 at 10:46 PM

$LAB we are heading much higher !!!!!!!!

1 · Reply

Xanderzzzzzzz Feb. 24 at 9:17 PM

$LAB https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-reports-fourth-quarter-and-full-year-2025

0 · Reply

StockNews_Live Feb. 24 at 9:13 PM

$LAB Standard BioTools Inc. announced financial results for the quarter and fiscal year ended December 31, 2025. The company reported revenue of $23.8 million for the fourth quarter and $85.3 million for t…

0 · Reply

StockNews_Live Feb. 24 at 9:10 PM

$LAB Standard BioTools reported fourth quarter and full year 2025 financial results. Revenue for the fourth quarter was $15.2 million, a decrease of 12% compared to the same period in 2024. Net loss for th…

0 · Reply

teksviler Feb. 24 at 3:34 PM

$LAB Adding right now. $ALMS $BE $THM USAR Some of my a bit risky plays.

1 · Reply

beckphan08 Feb. 24 at 1:38 PM

$LAB big Day. Better get this on track

1 · Reply

VJLer Feb. 22 at 9:18 PM

$LAB I'm curious to see what they are going to do with the $500.0 MM of cash they have. They reported $194.0 MM on 9/30/25 and then closed the trade sale after year end and generated another $300.0 MM or so in cash. And the blackout period for insiders trading ends 2 days after they announce. Going to be a little exciting over the next few weeks, i think.

3 · Reply

BillionerOfKing Feb. 20 at 2:01 PM

$LAB Current Stock Price: $1.15 Contracts to trade: $1.0 LAB Feb 20 2026 Call Entry: $0.36 Exit: $0.64 ROI: 78% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SmallStartLargeFinish Feb. 19 at 6:18 AM

$LAB this is going to reverse split and dilute at this rate

0 · Reply

GreenPond Feb. 15 at 8:56 PM

$LAB Besides the long-waited M&As, given so much cash at hand, will it be a good strategy to re-initiate stock repurchase program taking advantage of such low share price?

0 · Reply

Market Cap	358.65M
Revenue (ttm)	85.33M
Net Income (ttm)	-74.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-87.78%
Debt to Equity Ratio	0.00

Volume	2,086,400
Avg Vol	1,884,546
Day's Range	N/A - N/A
Shares Out	384.57M
Stochastic %K	4%
Beta	1.36
Analysts	Sell
Price Target	$1.55